Compounds and methods for treatment of viral infections
Inventors
Bunyan, Elaine • Chun, Byoung-Kwon • DEMPAH, Kassibla E. • Hui, Hon C • Kalla, Rao V. • Mackman, Richard L.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Compounds and methods of using said compounds, singly or in combination with additional agents, and salts, crystalline forms, pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
Core Innovation
The invention relates to crystalline forms of compounds of Formula, including Formula I, Formula Ia, and a compound of “Compound 15 HCl salt,” defined by an XRPD pattern. The crystalline form is characterized by having any three of the degree 2θ reflections (±0.2 degrees 2θ) selected from 9.8°, 10.2°, 10.4°, 16.0°, 19.1°, 19.8°, 20.7°, 25.4°, and 26.9°, and the disclosure uses this solid-state definition to distinguish crystalline forms, including Material A, Material B, and Material C.
The disclosure includes further crystalline-form defining features, including differential scanning calorimetry endothermic events at approximately 177°C and the specification that the crystalline form is unsolvated. It also describes solid forms including crystalline polymorphs, pseudopolymorphs, solvates/hydrates, and amorphous solids, and includes pharmaceutically acceptable salts.
The disclosure further relates the crystalline forms and compounds to antiviral activity and treatment of viral infections. The described viral targets include coronaviridae, including SARS-CoV-2 and COVID-19, and filoviridae, including Ebola and Marburg, and the document also provides in vitro antiviral potency and cytotoxicity assay descriptions together with in vivo pharmacokinetics and efficacy studies.
Claims Coverage
The relevant independent claims cover two crystalline forms of a compound of Formula characterized by XRPD reflection constraints. Across the dependent claims, the crystalline characterization is further refined by DSC endothermic behavior and an unsolvated physical form attribute, and the claims extend to pharmaceutical compositions and antiviral treatment contexts.
Crystalline form defined by XRPD reflections
A crystalline form of a compound of Formula wherein the crystalline form is characterized by an XRPD pattern having any three of the degree 2θ reflections (±0.2 degrees 2θ) at 9.8°, 10.2°, 10.4°, 16.0°, 19.1°, 19.8°, 20.7°, 25.4°, and 26.9°.
Crystalline form defined by XRPD reflections
A crystalline form of a compound of Formula wherein the crystalline form is characterized by an XRPD pattern having any three of the degree 2θ reflections (±0.2 degrees 2θ) at 9.8°, 10.2°, 16.0°, 19.1°, 25.4°, and 26.9°.
Dsc endothermic event characterization for the crystalline form
The crystalline form is characterized by a differential scanning calorimetry (DSC) pattern showing an endothermic event at approximately 177°C.
Unsolvated crystalline form limitation
The crystalline form is unsolvated.
Pharmaceutical composition including the crystalline form and pharmaceutically acceptable excipient
A pharmaceutical composition includes the crystalline form together with a pharmaceutically acceptable excipient.
Treatment of sars-cov-2 infection (covid-19)
The method is applied to a viral infection that is SARS-CoV-2 infection (COVID-19).
Treatment of filoviridae infection when ebola or marburg
The method is for treating a Filoviridae virus infection specifically when it is an Ebola virus infection or a Marburg virus infection.
Claim coverage centers on crystalline solid forms defined by XRPD reflection sets with any three specified degree 2θ reflections. Dependent claims further characterize the crystalline form with an approximately 177°C DSC endothermic event and an unsolvated form attribute, and extend coverage to pharmaceutical compositions containing the crystalline form and methods of treating viral infections, including SARS-CoV-2/COVID-19 and Filoviridae infections such as Ebola or Marburg.
Stated Advantages
The document provides antiviral activity and efficacy context across viral families.
The document provides stability characterization including GI S9, plasma, CES1/2, and hepatic S9, including comparative half-lives for Compound 1 and Compound 15.
Documented Applications
Pharmaceutical compositions including the crystalline form together with pharmaceutically acceptable excipients.
Treatment of viral infection, including SARS-CoV-2 infection (COVID-19) and Filoviridae virus infection where the infection is an Ebola virus infection or a Marburg virus infection.
Administration to humans for treating or preventing viral infections.
Interested in licensing this patent?